

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5672792

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	TEVA PHARMACEUTICALS INTERNATIONAL GMBH	04/10/2018
RECEIVING PARTY DATA		
Name:	XENON PHARMACEUTICALS INC.	
Street Address:	200 - 3650 GILMORE WAY	
City:	BURNABY, BC	
State/Country:	CANADA	
Postal Code:	V5G 4W8	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16156718
CORRESPONDENCE DATA		
Fax Number:	(206)682-6031	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	2066224900	
Email:	carolw@seedip.com	
Correspondent Name:	CAROL J. ROTH	
Address Line 1:	701 FIFTH AVENUE	
Address Line 2:	SUITE 5400	
Address Line 4:	SEATTLE, WASHINGTON 98104	
ATTORNEY DOCKET NUMBER:	480329.402D1 7OF 7	
NAME OF SUBMITTER:	CAROL J. ROTH	
SIGNATURE:	/Carol J. Roth/	
DATE SIGNED:	08/16/2019	
Total Attachments: 5		
source=Assign_TEVA_to_XENON#page1.tif		
source=Assign_TEVA_to_XENON#page2.tif		
source=Assign_TEVA_to_XENON#page3.tif		
source=Assign_TEVA_to_XENON#page4.tif		
source=Assign_TEVA_to_XENON#page5.tif		

PATENT ASSIGNMENT

THIS PATENT ASSIGNMENT (this "Patent Assignment") from Teva Pharmaceuticals International GmbH, formerly known as Ivax International GmbH, a Swiss limited liability company having its principal place of business at Schlüsselstrasse 12, 8645 Jona, Switzerland ("Assignor") to Xenon Pharmaceuticals, Inc., a corporation continued under the federal laws of Canada ("Assignee"), is effective as of March 27, 2018.

WHEREAS, Assignor and Assignee have entered into a Termination Agreement, dated as of March 7, 2018 (the "Termination Agreement"), pursuant to which, among other things, Assignor has agreed to assign to Assignee the Assigned Patents (as defined below).

1. Assigned Patents. The term "Assigned Patents" means the issued patents and pending patent applications set forth on Exhibit 1 attached hereto.

2. Assignment. For good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, Assignor hereby irrevocably assigns, transfers, sells and delivers to Assignee all of Assignor's right, title and interest in and to (i) the Assigned Patents and the inventions and improvements disclosed therein; (ii) all reissues, divisionals, continuations, continuations-in-part, extensions, renewals, reexaminations and foreign counterparts thereof; (iii) all patents and applications which claim priority to or have common priority with any such patents or patent applications; and (iv) all rights corresponding to any of the foregoing throughout the world, including the right to claim priority from any of the Assigned Patents, the right to prosecute and maintain any of the Assigned Patents, and the right to sue, claim remedies and recover damages for past, present and future infringement or other violation or impairment of any of the Assigned Patents, the same to be held and enjoyed by Assignee for its own use and enjoyment, and for the use and enjoyment of its successors, assigns and other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor, if this assignment had not been made.


3. Further Assurances. Assignor agrees that Assignee shall have the right to file or record this Patent Assignment with the United States Patent and Trademark Office or other such entities throughout the world, and Assignor authorizes and requests the relevant authorities to record Assignee as the assignee and owner of the Assigned Patents. Assignor shall execute and deliver to Assignee such documents and take such actions as requested by Assignee to register, evidence or perfect Assignee's rights under this Patent Assignment. In addition, Assignor hereby irrevocably designates and appoints Assignee and its duly authorized officers and agents as its agents and attorneys in fact, to act for and on their behalf and stead to execute and file any such documents and to do all other lawfully permitted acts to register, evidence or perfect Assignee's rights under this Patent Assignment with the same legal force and effect as if executed by Assignor. This includes, but is not limited to, the power to insert on this Patent Assignment any further identification that may be necessary to comply with the rules of the United States Patent and Trademark Office, or rules of other entities throughout the world, for recordation of this document.


4. Governing Law. This Patent Assignment shall be governed by, and construed in accordance with, the laws of the Province of Ontario and the laws of Canada in force therein, regardless of the laws that might otherwise govern under applicable principles of choice or conflicts of law thereof.

IN WITNESS WHEREOF, Assignor has caused this Patent Assignment to be executed as of the date first written above by its duly authorized officer.

ASSIGNOR SIGNATURE:

TEVA PHARMACEUTICALS INTERNATIONAL GMBH

By: 
Name: David Koch
President of the
Managing Officers
Title: _____
Date: April 10, 2018

By: 
Name: Naama Bar Am
General Manager
Title: _____
Date: _____

NOTARIZATION OF ASSIGNOR SIGNATURE:

ACKNOWLEDGMENT

Notarial Certificate

*lic.iur. Daniel Beeler M.B.L., Notary Public for the Canton St. Gallen (Switzerland), with
office at Untere Bahnhofstrasse 2, 8640 Rapperswil, Switzerland, hereby*

certifies:



the signatures on the reverse page were written in their own hands by

*Mrs. Naama BAR AM, born 6th January 1967, Israeli citizen, and
Mr. David KOCH, born 10th July 1955, Swiss citizen,*

both personally known to the notary.

Certified on the 11th day of April 2018

The notary public, Daniel Beeler



PATENT

REEL: 050082 FRAME: 0364

ASSIGNEE SIGNATURE:

XENON PHARMACEUTICALS INC.

By: [Signature]

Name: ROBIN SHERRINGTON, PhD

Title: VP, BUSINESS + CORPORATE DEVELOPMENT

Date: APRIL 30, 2018

NOTARIZATION OF ASSIGNEE SIGNATURE:

Province of British Columbia)
) ss.
Country of Canada)


I certify that I know or have satisfactory evidence that Robin Sherrington is the person who appeared before me, and said person acknowledged that he signed this instrument as an authorized representative of Xenon Pharmaceuticals Inc. and acknowledged it to be his free and voluntary act for the uses and purposes mentioned in the instrument.

Dated April 30 2018
Signature of Notary Public [Signature]
Printed Name Ozge Ozkan
Notary Public
3720 Canada Way
Burnaby, BC V5G 1G4
tel: 604-453-0290

My commission is for as long as I remain a practicing member of the Society of Notaries Public of British Columbia.

A Notary Public in and for the
Province of British Columbia

Permanent Commission



**EXHIBIT 1
ASSIGNED PATENTS**

Title	Application Number/ Patent Number	Filing Date	Issue Date	Inventor(s)	Owner/ Assignee	Status
Asymmetric Synthesis of Funapide	U.S. Patent Application No. 15/625,173	16-Jun- 2017	N/A	Ben-David Chen Christie Dimitri Gershon He Landmesser Levy Mizrahi Mudipalli Reese Solafani Wang	Teva Pharmaceuticals International GmbH	Pending
Asymmetric Synthesis of Funapide	PCT International Patent Application No. PCT/US2017/037921	16-Jun- 2017	N/A	Ben-David Chen Christie Dimitri Gershon He Landmesser Levy Mizrahi Mudipalli Reese Solafani Wang	Teva Pharmaceuticals International GmbH	Pending
Solid State Forms of Spiro-oxindole Compounds	U.S. Patent Application No. 15/625,724	16-Jun- 2017	N/A	Ben-David Bierlmaier Haltiwanger Jegorov Wu Yazdanian	Teva Pharmaceuticals International GmbH	Pending
Solid State Forms of Funapide	PCT International Patent Application No. PCT/US2017/037979	16-Jun- 2017	N/A	Ben-David Bierlmaier Haltiwanger Jegorov Wu Yazdanian	Teva Pharmaceuticals International GmbH	Pending
Methods of Treating Postherpetic Neuralgia with a Topical Formulation of a Spiro- Oxindole Compound	U.S. Patent No. 9,682,033	5-Feb- 2016	20-Jun- 2017	Petell Michael Goldberg Paul Lanson Michael Malamut Richard Price Nicola Spiegelstein Ofer	Teva Pharmaceuticals International GmbH	Granted